WO2002055081A3 - Use of chelators in the treatment of macular degenerative disease - Google Patents

Use of chelators in the treatment of macular degenerative disease Download PDF

Info

Publication number
WO2002055081A3
WO2002055081A3 PCT/IB2001/002265 IB0102265W WO02055081A3 WO 2002055081 A3 WO2002055081 A3 WO 2002055081A3 IB 0102265 W IB0102265 W IB 0102265W WO 02055081 A3 WO02055081 A3 WO 02055081A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chelators
degenerative disease
macular degenerative
prevention
Prior art date
Application number
PCT/IB2001/002265
Other languages
French (fr)
Other versions
WO2002055081A2 (en
Inventor
Michel Xilinas
Original Assignee
Michel Xilinas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel Xilinas filed Critical Michel Xilinas
Priority to EP01273136A priority Critical patent/EP1408969A2/en
Publication of WO2002055081A2 publication Critical patent/WO2002055081A2/en
Publication of WO2002055081A3 publication Critical patent/WO2002055081A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A use of clioquinol and phanoquinone for the manufacture of pharmaceutical compositions for the treatment and prevention of pathological conditions related with macular eye disease influenced by the action of matrix matalloproteinases (MMPs) is disclosed. Also methods of treatments or prevention of such conditions are disclosed.
PCT/IB2001/002265 2001-01-10 2001-11-28 Use of chelators in the treatment of macular degenerative disease WO2002055081A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01273136A EP1408969A2 (en) 2001-01-10 2001-11-28 Use of chelators in the treatment of macular degenerative disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0016369A FR2819187A1 (en) 2001-01-10 2001-01-10 USE OF CHELATING SUBSTANCES FOR THE TREATMENT AND PREVENTION OF EYE DEFERRESCENCE
FR00/16369 2001-01-10

Publications (2)

Publication Number Publication Date
WO2002055081A2 WO2002055081A2 (en) 2002-07-18
WO2002055081A3 true WO2002055081A3 (en) 2003-11-20

Family

ID=8857701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002265 WO2002055081A2 (en) 2001-01-10 2001-11-28 Use of chelators in the treatment of macular degenerative disease

Country Status (3)

Country Link
EP (1) EP1408969A2 (en)
FR (1) FR2819187A1 (en)
WO (1) WO2002055081A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
ZA200809493B (en) 2006-04-14 2010-08-25 Prana Biotechnology Ltd Method of treatment of age-related macular degeneration (AMD)
US20090018094A1 (en) * 2006-12-01 2009-01-15 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101566A (en) * 1996-09-27 1998-04-21 Kagaku Gijutsu Shinko Jigyodan Medicine for protecting retina
GB2345058A (en) * 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101566A (en) * 1996-09-27 1998-04-21 Kagaku Gijutsu Shinko Jigyodan Medicine for protecting retina
GB2345058A (en) * 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AHN Y H ET AL: "Depletion of intracellular zinc induces protein synthesis-dependent neuronal apoptosis in mouse cortical culture.", EXPERIMENTAL NEUROLOGY. UNITED STATES NOV 1998, vol. 154, no. 1, November 1998 (1998-11-01), pages 47 - 56, XP001164155, ISSN: 0014-4886 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2001 (2001-02-01), HYUN H J ET AL: "Depletion of intracellular zinc and copper with TPEN results in apoptosis of cultured human retinal pigment epithelial cells.", XP002252417, Database accession no. NLM11157883 *
DATABASE WPI Section Ch Week 199826, Derwent World Patents Index; Class B05, AN 1998-292043, XP002252418 *
HYUN HYAE JUNG ET AL: "Depletion of intracellular zinc induces macromolecule synthesis- and caspase-dependent apoptosis of cultured retinal cells.", BRAIN RESEARCH, vol. 869, no. 1-2, 2000, pages 39 - 48, XP001164156, ISSN: 0006-8993 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. UNITED STATES FEB 2001, vol. 42, no. 2, February 2001 (2001-02-01), pages 460 - 465, ISSN: 0146-0404 *
KAUFFMAN R E ET AL: "CLIOQUINOL IODOCHLORHYDROXYQUIN VIOFORM AND IODOQUINOL DIIODOHYDROXYQUIN BLINDNESS AND NEUROPATHY.", PEDIATRICS, (1990) 86 (5), 797-798., XP008020961 *

Also Published As

Publication number Publication date
EP1408969A2 (en) 2004-04-21
FR2819187A1 (en) 2002-07-12
WO2002055081A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
IL245956B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2004094596A8 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
EP1592435A4 (en) Ophthalmic formulation for the prevention and treatment of ocular conditions
WO2004072031A3 (en) Phenylacetamides and their use as glucokinase modulators
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2001066564A3 (en) Gamma-secretase inhibitors
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
WO2002094228A8 (en) Prevention and treatment of allergies by helminthic regulation of ige
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
WO2004077938A3 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
WO2003049667A3 (en) The method of treating cancer
WO2002055081A3 (en) Use of chelators in the treatment of macular degenerative disease
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
WO2001082912A3 (en) TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE
WO2001082911A3 (en) TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001273136

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001273136

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001273136

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP